| Treatment of intermediate stage hepatocellular carcinoma: a review of intrahepatic doxorubicin drug-delivery systems IR Dubbelboer, E Lilienberg, E Ahnfelt, E Sjögren, N Axén, H Lennernäs Therapeutic delivery 5 (4), 447-466, 2014 | 42 | 2014 |
| In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma E Lilienberg, IR Dubbelboer, A Karalli, R Axelsson, TB Brismar, ... Molecular pharmaceutics 14 (2), 448-458, 2017 | 38 | 2017 |
| Pharmacokinetics of total and unbound paclitaxel after administration of paclitaxel micellar or nab-paclitaxel: an open, randomized, cross-over, explorative study in breast … O Borgå, E Lilienberg, H Bjermo, F Hansson, N Heldring, R Dediu Advances in Therapy 36, 2825-2837, 2019 | 34 | 2019 |
| Investigation of hepatobiliary disposition of doxorubicin following intrahepatic delivery of different dosage forms E Lilienberg, C Ebeling Barbier, R Nyman, M Hedeland, U Bondesson, ... Molecular pharmaceutics 11 (1), 131-144, 2014 | 30 | 2014 |
| Maximum tolerated dose and pharmacokinetics of paclitaxel micellar in patients with recurrent malignant solid tumours: a dose-escalation study O Borgå, R Henriksson, H Bjermo, E Lilienberg, N Heldring, N Loman Advances in Therapy 36, 1150-1163, 2019 | 25 | 2019 |
| A model-based approach to assessing the importance of intracellular binding sites in doxorubicin disposition IR Dubbelboer, E Lilienberg, E Sjögren, H Lennernas Molecular pharmaceutics 14 (3), 686-698, 2017 | 25 | 2017 |
| Lipiodol-based emulsions used for transarterial chemoembolization and drug delivery: Effects of composition on stability and product quality E Ahnfelt, O Degerstedt, E Lilienberg, E Sjögren, P Hansson, ... Journal of Drug Delivery Science and Technology 53, 101143, 2019 | 23 | 2019 |
| The effects of lipiodol and cyclosporin A on the hepatobiliary disposition of doxorubicin in pigs IR Dubbelboer, E Lilienberg, M Hedeland, U Bondesson, ... Molecular Pharmaceutics 11 (4), 1301-1313, 2014 | 14 | 2014 |
| Lipiodol does not affect the tissue distribution of intravenous doxorubicin infusion in pigs E Lilienberg, IR Dubbelboer, E Sjögren, H Lennernäs Journal of Pharmacy and Pharmacology 69 (2), 135-142, 2017 | 7 | 2017 |
| Biopharmaceutical evaluation of intra-arterial drug-delivery systems for liver cancer: investigations in healthy pigs and liver cancer patients E Lilienberg Acta Universitatis Upsaliensis, 2015 | 4 | 2015 |
| Reply to" Comment on'In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma'" IR Dubbelboer, E Lilienberg, A Karalli, R Axelsson, TB Brismar, ... Molecular pharmaceutics 15 (1), 336-340, 2018 | 1 | 2018 |
| In vitro evaluation of lipiodol-based emulsions in clinical use E Ahnfelt, O Degerstedt, E Lilienberg, E Sjögren, P Hansson, ... | 1 | 2018 |
| Comparison of drug release, pharmacokinetics and pharmacodynamics after lipiodol-based emulsion or drug-eluting bead delivery to patients with hepatocellular carcinoma E Lilienberg, IR Dubbelboer, A Karalli, R Axelsson, TB Brismar, ... | | 2015 |
| Local and sustained release in the treatment of primary liver cancer? Pharmacokinetic understanding of two formulations for intra arterial injection E Lilienberg, C Ebeling Barbier, C Nyman, M Hedeland, U Bondesson, ... AAPS annual meeting and exposition, Chicago, USA, 2012 | | 2012 |
| Improved Pharmacokinetic Understanding of Two Formulations for Intra-arterial Injection E Lilienberg, C Ebeling Barbier, R Nyman, M Hedeland, U Bondesson, ... GPEN, Melbourne, Australia, 2012 | | 2012 |
| Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study OBRHH Bjermo, E Lilienberg, NHN Loman | | |
| Drug Eluting Beads vs. Lipiodol-based Emulsion regarding Local Drug Release and Effect in Patients with Hepatocellular Carcinoma–Interim Analysis of a Clinical Trial– E Lilienberg, IR Dubbelboer, A Karalli, P Stål, CE Barbier, A Norén, ... | | |
| Application of PBBP Modeling to Liver Targeted Drug Delivery Systems IR Dubbelboer, E Lilienberg, E Sjögren, H Lennernäs | | |
Erik SjögrenPhD BiopharmaceuticsVerifierad e-postadress på farmaci.uu.se
